Metrion Biosciences has appointed Dr. Barry Kenny and Dr. Andrew Southan to its Board of Directors. The appointments have been made to strengthen the focus on commercial and business development capabilities.   Dr. Kenny is chief business officer of Heptares Therapeutics. He was previously vice president, Drug Discovery at Takeda Cambridge, and commercial director at Paradigm Therapeutics.    Dr. Southan joined Metrion as head of Commercial Operations in October 2016, and was pro...